BCRX vs COO
BioCryst Pharmaceuticals, Inc. vs Cooper Companies (The) — AI-powered side-by-side comparison
BCRX
BioCryst Pharmaceuticals, Inc.
66
Buy
VS
COO
Cooper Companies (The)
68
Buy
| Metric | BCRX | COO |
|---|
| AI Score |
66
|
68
|
| Price |
$9.81
|
$73.45
|
| P/E Ratio |
-6.73×
|
64.24×
|
| ROE |
-221.4%
|
4.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
23.5%
|
64.4%
|
| Debt / Equity |
-0.90×
|
0.30×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
48.8
|
54.1
|
| Beta |
0.554
|
0.823
|
| Expected Upside |
+1.3%
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for BCRX versus COO.
COO leads by 2 points.
COO scores 68/100 (Buy) versus BCRX at 66/100 (Buy).
BCRX Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 18.9% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Bollinger bandwidth of 18.9% signals elevated volatility — Risk
COO Committee View
80% agreement
5 analysts
The primary driver is 4 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical